NERV - Minerva Neurosciences, Inc.
| Previous Close | 12.15 |
| Open | 12.15 |
| Bid | 12.30 x 1300 |
| Ask | 12.35 x 1200 |
| Day's Range | 12.00 - 12.50 |
| 52 Week Range | 4.80 - 12.50 |
| Volume | 224,006 |
| Avg. Volume | 185,750 |
| Market Cap | 480.801M |
| Beta | 1.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.92 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.00 |
- Zacks•19 days ago
J&J Submits NDA to the FDA for Depression Drug in Adults
Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.
- Benzinga•last month
The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 22) Acer Therapeutics Inc (NASDAQ: ACER ) Avanos Medical Inc (NYSE: ...
- GlobeNewswire•last month
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced findings from a recent pre-clinical study that provide evidence of the effect of roluperidone (MIN-101) on BDNF. Data from this study are being presented today at the Medicxi Forum in Venice, Italy showing that after three days of administration, roluperidone has been observed to significantly increase the release of BDNF in cultured brain hippocampal neurons in a dose dependent manner. Dysregulation of BDNF has been described in the pathophysiology of schizophrenia and several other neuro-psychiatric disorders.
- GlobeNewswire•last month
New Research Coverage Highlights EMCORE, Earthstone Energy, Pareteum, Lydall, Minerva Neurosciences, and Drive Shack — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Aug. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EMCORE ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of NERV earnings conference call or presentation 2-Aug-18 12:30pm GMT
Q2 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•2 months ago
Minerva Neurosciences: 2Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 32 cents per share. Minerva Neurosciences shares have climbed 32 percent since the beginning of the year. The stock has increased 13 percent ...
- GlobeNewswire•2 months ago
Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates
WALTHAM, Mass., Aug. 02, 2018-- Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported ...
- GlobeNewswire•2 months ago
Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
Management to host conference call WALTHAM, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of ...
- GlobeNewswire•2 months ago
Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
WALTHAM, Mass., July 26, 2018-- Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced ...
- GlobeNewswire•2 months ago
Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel
WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...
- GlobeNewswire•2 months ago
Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel
WALTHAM, Mass., July 25, 2018-- Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced ...
- GlobeNewswire•2 months ago
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...
- GlobeNewswire•2 months ago
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors
WALTHAM, Mass., July 17, 2018-- Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced ...
- GlobeNewswire•4 months ago
Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018
WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central ...
- GlobeNewswire•4 months ago
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp...
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders (CNS), today announced that The Journal of Clinical Psychiatry has published online results demonstrating cognitive improvements in patients with schizophrenia treated with roluperidone (MIN-101). The results also demonstrated that cognitive improvements correlate with previously reported improvements in negative symptoms. Roluperidone is a novel compound with affinities for 5HT2A and sigma2 receptors and no direct binding to dopamine receptors.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMT
Q1 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•5 months ago
Minerva Neurosciences: 1Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 32 cents. Minerva Neurosciences shares have risen 14 percent since the beginning of the year. The stock has fallen nearly ...
- GlobeNewswire•5 months ago
Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...
- GlobeNewswire•5 months ago
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
Management to host conference call WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of ...
